Author name: Swaraj Paul Barooah

.

Guest Post: Online System does not support high value patent filing transactions

/ By / Others, Patent

Recently we wrote about the number of welcome measures taken by the Patent office with regard to transparency and efficiency, including the online payment gateway. While we certainly applaud these measures, it appears there are a couple of creases yet to be ironed out. We bring you a guest post from Jitin Talwar on an issue that’s cropped up with the online filing system when transactions over Rs 5 lakhs are involved. As he points out, given that now prices […]

Guest Post: Online System does not support high value patent filing transactions Read More »

generic stock photo

Guest Post: Where Do We Stand on ‘Secondary Electronic Evidence’?

/ By / Others

We’re happy to present to our readers a useful guest post by Aradhya Sethia, a student at NLSIU, Bangalore. In this post, Aradhya looks at a recent Supreme Court case’s take on Secondary Electronic Evidence and some of its implications. The Case of Anvar P.V. v. P.V. Basheer and Others: Where Do We Stand on ‘Secondary Electronic Evidence’? The role of Secondary Electronic Evidence and the Structure of Section 65B of the Evidence Act Albeit in varying degrees, we all

Guest Post: Where Do We Stand on ‘Secondary Electronic Evidence’? Read More »

India shoots unilateral USTR action down; Looks towards bilateral talks

/ By / Others

In a very welcome and quick response to USTR’s Special 301 Out of Cycle Review (OCR) process for India that opened for comments a couple of days ago (October 14th), the Government of India has told the American authorities that they will not be cooperating with this unilateral process, writes Nayanima Basu in the Business Standard. Pointing to the lack of any obligation to participate in the unilaterally held Special 301 process, Indian authorities have said that they would engage US

India shoots unilateral USTR action down; Looks towards bilateral talks Read More »

India-US IP working groups insufficient for USTR – Continuing with unilateral OCR as well

/ By / Others

According to the US Federal Register, it appears the US Trade Representative will proceed with an Out of Cycle Review (OCR) for India to unilaterally ‘grade’ India’s IPR regime as they had announced earlier this year. This throws up two quick points that need mentioning/repeating: 1. The USTR Special 301 annual process is a degrading political pressure mechanism with no credibility.  The above link states: “… in order to assess progress on engagement with the Government of India on intellectual property rights

India-US IP working groups insufficient for USTR – Continuing with unilateral OCR as well Read More »

Tango Trademark Trouble

/ By / Trademark

We’re happy to bring our readers a note on a recent Bombay High court order, by Shashank Mangal and Kamlesh Mali, students from ILS Law College, Pune. I must state up front that though they had sent this to me almost immediately after the order had been passed, there was a long delay on my part in posting it. Without further ado: Interpretation of S.17 and S.30 (1) (a) of the Trade Mark Act, 1999 with reference to a recent

Tango Trademark Trouble Read More »

Guest Post: “India’s misguided response to our findings on the quality of drug exports”

/ By / Drug Regulation, Others

We recently wrote a two part piece on an NBER paper that has been garnering quite a bit of attention for two reasons. First, because the authors conclude that India’s pharmaceutical companies may be discriminating against African nations in their exports; and secondly, because the Indian government has indicated they may file a defamation action against the authors for this paper. In covering these developments, first I presented some of my critiques of the paper; and then, Gautam Bhatia wrote

Guest Post: “India’s misguided response to our findings on the quality of drug exports” Read More »

New Online IPR/Media/Tech Resources – For Students, Teachers and Researchers

/ By / Others

We’ve recently come across some wonderful new resources that our readers may be interested in. As it’s often difficult to know what information is available where, and since it would be a shame if these wonderful new resources went undiscovered, I thought I’d list out some of those that have caught my eye over the last few months. I’ve tried to focus on resources that are ‘open’, relatively new, and that would be useful for students, teachers and researchers in

New Online IPR/Media/Tech Resources – For Students, Teachers and Researchers Read More »

Trouble Brewing around NBER Paper on Indian Pharma – Part II

/ By / Others, Patent

Yesterday, I wrote about the big storm brewing around an NBER paper which claimed that the Indian pharma industry was intentionally sending lower quality drugs to African countries. In response to this paper, it appears the Government of India may be launching legal proceedings. In yesterday’s post, I discussed the paper itself – concluding that the paper in its current state was not quite convincing in its own conclusions. [The lead author has responded to a few points in the comments

Trouble Brewing around NBER Paper on Indian Pharma – Part II Read More »

Trouble Brewing around NBER Paper on Indian Pharma – Part I

/ By / Patent

We’ve recently been informed of two events, one flowing from the other, both of which I would term as very disturbing in their own way. First, is this NBER Working Paper that concludes that it is likely that Indian pharmaceutical firms differentiate drug quality based on destination of consumption, to the detriment of African countries. Secondly, is the follow up development that the Indian government may be taking legal action against the authors of the above paper. Needless to say – both

Trouble Brewing around NBER Paper on Indian Pharma – Part I Read More »

Cancer drug price is NOT going from Rs 8000 to Rs 1.08lakhs!

/ By / Patent

There seems to be a lot of mis-information around the latest supposed “cap” on National Pharmaceutical Pricing Authority (NPPA)’s powers. I thought I would try to clear some of this up. 1. Why exactly is the NPPA’s power being reduced? It’s technically not being reduced. It’s being clarified. As Madhulika pointed out in our post on the topic: The government noted that the NPPA was stepping beyond its given powers by interpreting “extraordinary circumstances … in public interest” in a

Cancer drug price is NOT going from Rs 8000 to Rs 1.08lakhs! Read More »

Scroll to Top